Social Determinants of Health and their Impact on COVID-19

Immunological and Autoimmune Disorders

AbbVie Presents Phase III CANOVA Study Results;...

AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie has released findings from its Phase III CANOVA trial, which assess...

Oct 03, 2023

Pharma News for BMS, Alnylam, MaaT Pharma
BMS’s LPA1 Antagonist; Alnylam’s KARDIA-1 Phase 2 Study; Day One Biopharma Sought FDA Approval for Tovorafenib; EMA Orphan Drug Designation to MaaT Pharma’s MaaT033; Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole + Sertraline; Phase III CheckMate – 227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy

Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase II Study BMS-986278, a potential first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, was studied in patients with progressive pulmonary fibrosis (PPF)...

Find More
Pharma News for Biogen, Astellas, Ascentage
FDA Approves ZURZUVAE for Postpartum Depression; Astellas Drug Acquired in $5.9B Deal Wins FDA Approval; FDA Clearance to Phase III Study of Lisaftoclax; FDA Issues CRL to BLA Resubmission for Remestemcel-L; Bavarian Nordic Updated on its Chikungunya Virus Vaccine; FDA Orphan Drug Designation to ABM-1310

FDA Approves ZURZUVAE, the First and Only Oral Treatment Approved for Women with Postpartum Depression Biogen Inc. and Sage Therapeutics, Inc. announced that the FDA has approved ZURZUVAE (zuranolone) 50 mg for individuals with postpartum depression (PPD). ZURZUVAE is the first and only 14-day oral, once-daily t...

Find More
Nutricosmetics Market Outlook
Evaluating the Evolving Trends in the Nutricosmetics Market: The Intersection of Nutrition and Skincare

The desire for natural beauty that can improve one's health and appearance without having any negative side effects is rising as consumers are becoming more cautious about the food they eat and the products they introduce into their bodies. Nutricosmetics are one such category of product that fit with the modern cu...

Find More

More Views & Analysis

graft-versus-host-disease-gvhd-treatment
Graft-Versus-Host Disease (GvHD) Treatment Market: A Moving Target For Therapies

Allogeneic HSCT is a mainstay for patients with different hematological malignancies, but it requires immunosuppressive strategies before and after HSCT. However, approximately half (50%) of the patients receiving allogeneic hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-matched ...

Find More

Gene Therapies for Dystrophic Epidermolysis Bullosa
Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?

Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by changes in the COL7A1 gene. In this rare condition, blisters form on the skin and the moist inner lining of some organs and body cavities. Depending upon the nature of the inheritance pattern, dystrophic epidermolysis bullosa is divided into ...

Find More

Pharma News for Pfizer, Daiichi Sankyo, Kyverna, Servier
Daiichi Sankyo’s Intravenous Iron Replacement Therapy; ANeuroTech’s Adjunctive Anti-depression Drug, ANT-01; Kyverna Therapeutics’s KYV-101 in Lupus Nephritis; Servier Presents Data from Phase 3 INDIGO Trial of Vorasidenib; FDA Approves Pfizer’s ABRYSVO

FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults Pfizer Inc. announced that the FDA has authorized ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory...

Find More

anca-associated-vasculitis-treatment
ANCA-associated Vasculitis Treatment Market: Unraveling the Complexities

ANCA-associated vasculitis is a rare, life-threatening autoimmune disease with a relapsing nature. ANCA-Associated vasculitis comprises three autoimmune disorders, i.e. Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). The global yearly...

Find More

emerging-tlr-7-8-agonists
Role of TLR7/8 Agonists in Treating Various Cancers

The Toll family of receptors includes several related proteins involved in plant and animal development and defense. Mammalian TLRs are a large family with at least 11 members, of which humans encode the first ten. Individual TLRs are critical in recognizing pathogen-derived microbial components such as bacteria, f...

Find More

emerging-drugs-for-plaque-psoriasis-treatment
What Does the Future of Plaque Psoriasis Treatment Market Look Like?

Psoriasis is a common skin condition that accelerates the life cycle of skin cells. More than 3% of the adult population in the United States suffers from psoriasis. That equates to more than 7.5 million US adults. According to the World Psoriasis Day Consortium, 125 million people worldwide (2-3% of the total popu...

Find More

An inflammatory disease of large intestine, Ulcerative Colitis (UC), is approached with therapies th.....

Find More

Virtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with t.....

Find More

BK Virus Infection , a member of the polyomavirus family, is typically associated with patients who .....

Find More

Asthma is a chronic disease of the air passages characterized by inflammation and narrowing of the a.....

Find More

Cancer, an immunologic condition that can begin in any organ or tissue of the body is the second lea.....

Find More

Lamellar Ichthyosis (LI) is an autosomal recessive congenital Ichthyosis (ARCI), which mainly affect.....

Find More